Winning Stock Forecast: Biopharma Company Amarin Corporation PLC (NASDAQ: AMRN) Brings 16.01 % In 7 Days

AMRN Winning Stock Forecast

Source: kisspng.com

This week biopharma company AMRN saw a 16.01 % jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. Heart Disease is still the leading factor for deaths in the USA and following recent patient trials Vascepa users are 25% less likely to suffer from a cardiac arrest. These impressive results thrust Vascepa as the industry leader drug for those suffering with high cholesterol.

Amarin Corporation lost $92 million this year because sales of Vascepa just haven’t kept pace with operating expenses. However, they are putting huge investment into turning their drug Vascepa into a ‘blockbuster.’ Many critics are often sceptical about such investment but in this case it appears that Amarin may be an exception. With a positive trail the market reaction has seen Amarin as a company with long term potential and investors will continue to support this drug.

Source: maxpixel.net

Current I Know First subscribers received a bullish AMRN forecast on October 11th. With a strong signal of 31.89 for the week-long time frame.

Traders and investors utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers on October 11th.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

About

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers